BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28245093)

  • 1. Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism.
    Lougiakis N; Frakolaki E; Karmou P; Pouli N; Marakos P; Madan V; Bartenschlager R; Vassilaki N
    Chem Biol Drug Des; 2017 Sep; 90(3):352-367. PubMed ID: 28245093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and anti-HCV activity of a new 2'-deoxy-2'-fluoro-2'-C-methyl nucleoside analogue.
    Hu W; Wang P; Song C; Pan Z; Wang Q; Guo X; Yu X; Shen Z; Wang S; Chang J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7297-8. PubMed ID: 21106452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside analog inhibitors of hepatitis C virus replication.
    Carroll SS; Olsen DB
    Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
    Feng JY; Cheng G; Perry J; Barauskas O; Xu Y; Fenaux M; Eng S; Tirunagari N; Peng B; Yu M; Tian Y; Lee YJ; Stepan G; Lagpacan LL; Jin D; Hung M; Ku KS; Han B; Kitrinos K; Perron M; Birkus G; Wong KA; Zhong W; Kim CU; Carey A; Cho A; Ray AS
    Antimicrob Agents Chemother; 2014; 58(4):1930-42. PubMed ID: 24419349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3'-Deoxy phosphoramidate dinucleosides as improved inhibitors of hepatitis C virus subgenomic replicon and NS5B polymerase activity.
    Priet S; Zlatev I; Barvik I; Geerts K; Leyssen P; Neyts J; Dutartre H; Canard B; Vasseur JJ; Morvan F; Alvarez K
    J Med Chem; 2010 Sep; 53(18):6608-17. PubMed ID: 20799693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
    Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
    Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of hepatitis C virus NS5A inhibitors.
    Lemm JA; O'Boyle D; Liu M; Nower PT; Colonno R; Deshpande MS; Snyder LB; Martin SW; St Laurent DR; Serrano-Wu MH; Romine JL; Meanwell NA; Gao M
    J Virol; 2010 Jan; 84(1):482-91. PubMed ID: 19812153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-HCV activity of 3',4'-oxetane nucleosides.
    Chang W; Du J; Rachakonda S; Ross BS; Convers-Reignier S; Yau WT; Pons JF; Murakami E; Bao H; Steuer HM; Furman PA; Otto MJ; Sofia MJ
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4539-43. PubMed ID: 20580554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
    Camus G; Xu S; Han B; Lu J; Dvory-Sobol H; Yu M; Cheng G; Miller MD; Doehle BP; Mo H
    Virology; 2018 Jan; 514():134-141. PubMed ID: 29175627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
    Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
    J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase.
    Di Francesco ME; Avolio S; Pompei M; Pesci S; Monteagudo E; Pucci V; Giuliano C; Fiore F; Rowley M; Summa V
    Bioorg Med Chem; 2012 Aug; 20(15):4801-11. PubMed ID: 22770556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.